
Sepsis Diagnostics Market Report and Forecast 2025-2034
Description
The global sepsis diagnostics market size was valued at USD 725.60 Million in 2024, driven by the rising merger and acquisitions amongst companies to offer early diagnosis of the condition. The market is expected to grow at a CAGR of 9.10% during the forecast period of 2025-2034, with the values likely to reach USD 1733.58 Million by 2034.
Sepsis Diagnostics: Introduction
Sepsis is a condition characterized by the body’s abnormal response to an infection. Common symptoms may include sweating, shivering, change in mental status, and shallow breathing, among others. The condition can be diagnosed via blood tests, which help in detecting evidence of infection, abnormal liver or kidney function, electrolyte imbalances or blood clotting issues. The imaging tests may include x-ray, ultrasound, CT scans, and MRIs.
Global Sepsis Diagnostics Market Analysis
Sepsis is one of the leading causes of deaths in the world. As per studies, early diagnosis can significantly help lower the fatalities associated with the condition. Therefore, there has been rising demand for sepsis diagnostics.
The sepsis diagnostics market growth is driven by the rising merger and acquisitions amongst companies to offer early diagnosis of the condition. In September 2023, Acutelines, a data-biobank and Inflammatix, a molecular diagnostics company announced their strategic partnership to develop a smart tool that helps in the recognition of sepsis while supporting clinical decisions in the early stages of the disease. This can mark as a crucial step since early recognition can be quite difficult in this condition.
With deeper understanding of human physiology and improved biotechnology techniques, the market for sepsis diagnostics has been experiencing major advancements. For instance, In November 2023, Abionic, along with their biomedical technology partner Lascco, entered a licensing agreement with Fapon, to utilize the pancreatic stone protein (PSP) biomarker for sepsis diagnosis.
SeptiCyte® RAPID by Immunexpress is another molecular test for sepsis diagnosis that employs the RT-PCR test to quantify the level of host response genes. It is intended for in-vitro diagnostic use and runs on the Biocartis Idylla™ Platform. Emerging technologies like these will certainly benefit the sepsis diagnostics market value in the forecast period.
Global Sepsis Diagnostics Market Segmentation
“Sepsis Diagnostics Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:
Market Breakup by Product Type Polymerase Chain Reaction (PCR)
DNA Microarrays
Syndromic Panel Testing
Others Gram-positive Bacteria
Gram-negative Bacteria
The United States holds a substantial part of the sepsis diagnostics market share owing to a robust healthcare infrastructure. Increasing effort of the government and private institutions to offer awareness about the condition also plays a vital role for market growth. In July 2023, the Society of Critical Care Medicine (SCCM) received a grant from the Council of Medical Specialty Societies to enhance diagnostic excellence. The diagnostic program by SCCM focuses on providing knowledge and technology for precise diagnosis with the help of podcasts, toolkits, and webcasts.
The Asia Pacific region is projected to witness further growth with the increasing sepsis diagnostics market demand in the region. With increasing mergers and collaborations, the government has also been working on improving the medical infrastructure with a vision to integrate all digital and artificial intelligence-based tools into the system. A large population base spanning from the old as well as young generations is another essential factor for increased market demand.
Global Sepsis Diagnostics Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
*Please Note:* The report will take 5 business days to complete, after order confirmation.
Sepsis Diagnostics: Introduction
Sepsis is a condition characterized by the body’s abnormal response to an infection. Common symptoms may include sweating, shivering, change in mental status, and shallow breathing, among others. The condition can be diagnosed via blood tests, which help in detecting evidence of infection, abnormal liver or kidney function, electrolyte imbalances or blood clotting issues. The imaging tests may include x-ray, ultrasound, CT scans, and MRIs.
Global Sepsis Diagnostics Market Analysis
Sepsis is one of the leading causes of deaths in the world. As per studies, early diagnosis can significantly help lower the fatalities associated with the condition. Therefore, there has been rising demand for sepsis diagnostics.
The sepsis diagnostics market growth is driven by the rising merger and acquisitions amongst companies to offer early diagnosis of the condition. In September 2023, Acutelines, a data-biobank and Inflammatix, a molecular diagnostics company announced their strategic partnership to develop a smart tool that helps in the recognition of sepsis while supporting clinical decisions in the early stages of the disease. This can mark as a crucial step since early recognition can be quite difficult in this condition.
With deeper understanding of human physiology and improved biotechnology techniques, the market for sepsis diagnostics has been experiencing major advancements. For instance, In November 2023, Abionic, along with their biomedical technology partner Lascco, entered a licensing agreement with Fapon, to utilize the pancreatic stone protein (PSP) biomarker for sepsis diagnosis.
SeptiCyte® RAPID by Immunexpress is another molecular test for sepsis diagnosis that employs the RT-PCR test to quantify the level of host response genes. It is intended for in-vitro diagnostic use and runs on the Biocartis Idylla™ Platform. Emerging technologies like these will certainly benefit the sepsis diagnostics market value in the forecast period.
Global Sepsis Diagnostics Market Segmentation
“Sepsis Diagnostics Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:
Market Breakup by Product Type
- Instruments
- Blood Culture Media
- Assay Kits and Reagents
- Software
- Microbiology
- Molecular Diagnostics
- Immunoassays
- Flow Cytometry
- Others
- Bacterial Sepsis
- Fungal Sepsis
- Viral Sepsis
- Others
- Laboratory Testing
- POC Testing
- Automated Diagnostics
- Conventional Diagnostics
- Hospitals and Clinics
- Pathology and Reference Laboratories
- Research Institutes
- Others
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
The United States holds a substantial part of the sepsis diagnostics market share owing to a robust healthcare infrastructure. Increasing effort of the government and private institutions to offer awareness about the condition also plays a vital role for market growth. In July 2023, the Society of Critical Care Medicine (SCCM) received a grant from the Council of Medical Specialty Societies to enhance diagnostic excellence. The diagnostic program by SCCM focuses on providing knowledge and technology for precise diagnosis with the help of podcasts, toolkits, and webcasts.
The Asia Pacific region is projected to witness further growth with the increasing sepsis diagnostics market demand in the region. With increasing mergers and collaborations, the government has also been working on improving the medical infrastructure with a vision to integrate all digital and artificial intelligence-based tools into the system. A large population base spanning from the old as well as young generations is another essential factor for increased market demand.
Global Sepsis Diagnostics Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- BioMérieux SA
- Becton, Dickinson and Company
- Thermo Fisher Scientific, Inc.
- F. Hoffmann-La Roche AG
- Danaher Corporation
- Luminex Corp.
- Bruker Corp.
- Cepheid
- Bruker Corporation
- Immunexpress, Inc.
- Nanosphere, Inc.
- Seegene Inc.
- Response Biomedical Corp.
- Quidel Corporation
- Koninklijke Philips N.V.
*Please Note:* The report will take 5 business days to complete, after order confirmation.
Table of Contents
350 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Sepsis Diagnostics Market Overview
- 3.1 Global Sepsis Diagnostics Market Historical Value (2018-2024)
- 3.2 Global Sepsis Diagnostics Market Forecast Value (2025-2034)
- 4 Global Sepsis Diagnostics Market Landscape
- 4.1 Global Sepsis Diagnostics Developers Landscape
- 4.1.1 Analysis by Year of Establishment
- 4.1.2 Analysis by Company Size
- 4.1.3 Analysis by Region
- 4.2 Global Sepsis Diagnostics Product Landscape
- 4.2.1 Analysis by Type
- 4.2.2 Analysis by Technology
- 4.2.3 Analysis by Pathogen
- 5 Global Sepsis Diagnostics Market Dynamics
- 5.1 Market Drivers and Constraints
- 5.2 SWOT Analysis
- 5.3 Porter’s Five Forces Model
- 5.4 Key Demand Indicators
- 5.5 Key Price Indicators
- 5.6 Industry Events, Initiatives, and Trends
- 5.7 Value Chain Analysis
- 6 Global Sepsis Diagnostics Market Segmentation
- 6.1 Global Sepsis Diagnostics Market by Product Type
- 6.1.1 Market Overview
- 6.1.2 Instruments
- 6.1.3 Blood Culture Media
- 6.1.4 Assay Kits and Reagents
- 6.1.5 Software
- 6.2 Global Sepsis Diagnostics Market by Technology
- 6.2.1 Market Overview
- 6.2.2 Microbiology
- 6.2.3 Molecular Diagnostics
- 6.2.3.1 Polymerase Chain Reaction (PCR)
- 6.2.3.2 DNA Microarrays
- 6.2.3.3 Syndromic Panel Testing
- 6.2.3.4 Others
- 6.2.4 Immunoassays
- 6.2.5 Flow Cytometry
- 6.2.6 Others
- 6.3 Global Sepsis Diagnostics Market by Pathogen
- 6.3.1 Market Overview
- 6.3.2 Bacterial Sepsis
- 6.3.2.1 Gram-positive Bacteria
- 6.3.2.2 Gram-negative Bacteria
- 6.3.3 Fungal Sepsis
- 6.3.4 Viral Sepsis
- 6.3.5 Others
- 6.4 Global Sepsis Diagnostics Market by Type
- 6.4.1 Market Overview
- 6.4.2 Laboratory Testing
- 6.4.3 POC Testing
- 6.5 Global Sepsis Diagnostics Market by Methods
- 6.5.1 Market Overview
- 6.5.2 Automated Diagnostics
- 6.5.3 Conventional Diagnostics
- 6.6 Global Sepsis Diagnostics Market by End User
- 6.6.1 Market Overview
- 6.6.2 Hospitals and Clinics
- 6.6.3 Pathology and Reference Laboratories
- 6.6.4 Research Institutes
- 6.6.5 Others
- 6.7 Global Sepsis Diagnostics Market by Region
- 6.7.1 Market Overview
- 6.7.2 North America
- 6.7.3 Europe
- 6.7.4 Asia Pacific
- 6.7.5 Latin America
- 6.7.6 Middle East and Africa
- 7 North America Sepsis Diagnostics Market
- 7.1 Market Share by Country
- 7.2 United States of America
- 7.3 Canada
- 8 Europe Sepsis Diagnostics Market
- 8.1 Market Share by Country
- 8.2 United Kingdom
- 8.3 Germany
- 8.4 France
- 8.5 Italy
- 8.6 Others
- 9 Asia Pacific Sepsis Diagnostics Market
- 9.1 Market Share by Country
- 9.2 China
- 9.3 Japan
- 9.4 India
- 9.5 ASEAN
- 9.6 Australia
- 9.7 Others
- 10 Latin America Sepsis Diagnostics Market
- 10.1 Market Share by Country
- 10.2 Brazil
- 10.3 Argentina
- 10.4 Mexico
- 10.5 Others
- 11 Middle East and Africa Sepsis Diagnostics Market
- 11.1 Market Share by Country
- 11.2 Saudi Arabia
- 11.3 United Arab Emirates
- 11.4 Nigeria
- 11.5 South Africa
- 11.6 Others
- 12 Patent Analysis
- 12.1 Analysis by Type of Patent
- 12.2 Analysis by Publication year
- 12.3 Analysis by Issuing Authority
- 12.4 Analysis by Patent Age
- 12.5 Analysis by CPC Analysis
- 12.6 Analysis by Patent Valuation
- 12.7 Analysis by Key Players
- 13 Grants Analysis
- 13.1 Analysis by year
- 13.2 Analysis by Amount Awarded
- 13.3 Analysis by Issuing Authority
- 13.4 Analysis by Grant Application
- 13.5 Analysis by Funding Institute
- 13.6 Analysis by NIH Departments
- 13.7 Analysis by Recipient Organization
- 14 Funding Analysis
- 14.1 Analysis by Funding Instances
- 14.2 Analysis by Type of Funding
- 14.3 Analysis by Funding Amount
- 14.4 Analysis by Leading Players
- 14.5 Analysis by Leading Investors
- 14.6 Analysis by Geography
- 15 Partnership and Collaborations Analysis
- 15.1 Analysis by Partnership Instances
- 15.2 Analysis by Type of Partnership
- 15.3 Analysis by Leading Players
- 15.4 Analysis by Geography
- 16 Regulatory Framework
- 16.1 Regulatory Overview
- 16.1.1 US FDA
- 16.1.2 EU EMA
- 16.1.3 INDIA CDSCO
- 16.1.4 JAPAN PMDA
- 16.1.5 Others
- 17 Supplier Landscape
- 17.1 BioMérieux SA
- 17.1.1 Financial Analysis
- 17.1.2 Product Portfolio
- 17.1.3 Demographic Reach and Achievements
- 17.1.4 Mergers and Acquisition
- 17.1.5 Certifications
- 17.2 Becton, Dickinson and Company
- 17.2.1 Financial Analysis
- 17.2.2 Product Portfolio
- 17.2.3 Demographic Reach and Achievements
- 17.2.4 Mergers and Acquisition
- 17.2.5 Certifications
- 17.3 Thermo Fisher Scientific, Inc.
- 17.3.1 Financial Analysis
- 17.3.2 Product Portfolio
- 17.3.3 Demographic Reach and Achievements
- 17.3.4 Mergers and Acquisition
- 17.3.5 Certifications
- 17.4 F. Hoffmann-La Roche AG
- 17.4.1 Financial Analysis
- 17.4.2 Product Portfolio
- 17.4.3 Demographic Reach and Achievements
- 17.4.4 Mergers and Acquisition
- 17.4.5 Certifications
- 17.5 Danaher Corporation
- 17.5.1 Financial Analysis
- 17.5.2 Product Portfolio
- 17.5.3 Demographic Reach and Achievements
- 17.5.4 Mergers and Acquisition
- 17.5.5 Certifications
- 17.6 Luminex Corp.
- 17.6.1 Financial Analysis
- 17.6.2 Product Portfolio
- 17.6.3 Demographic Reach and Achievements
- 17.6.4 Mergers and Acquisition
- 17.6.5 Certifications
- 17.7 Bruker Corp.
- 17.7.1 Financial Analysis
- 17.7.2 Product Portfolio
- 17.7.3 Demographic Reach and Achievements
- 17.7.4 Mergers and Acquisition
- 17.7.5 Certifications
- 17.8 Cepheid
- 17.8.1 Financial Analysis
- 17.8.2 Product Portfolio
- 17.8.3 Demographic Reach and Achievements
- 17.8.4 Mergers and Acquisition
- 17.8.5 Certifications
- 17.9 Bruker Corporation
- 17.9.1 Financial Analysis
- 17.9.2 Product Portfolio
- 17.9.3 Demographic Reach and Achievements
- 17.9.4 Mergers and Acquisition
- 17.9.5 Certifications
- 17.10 Immunexpress, Inc.
- 17.10.1 Financial Analysis
- 17.10.2 Product Portfolio
- 17.10.3 Demographic Reach and Achievements
- 17.10.4 Mergers and Acquisition
- 17.10.5 Certifications
- 17.11 Nanosphere, Inc.
- 17.11.1 Financial Analysis
- 17.11.2 Product Portfolio
- 17.11.3 Demographic Reach and Achievements
- 17.11.4 Mergers and Acquisition
- 17.11.5 Certifications
- 17.12 Seegene Inc.
- 17.12.1 Financial Analysis
- 17.12.2 Product Portfolio
- 17.12.3 Demographic Reach and Achievements
- 17.12.4 Mergers and Acquisition
- 17.12.5 Certifications
- 17.13 Response Biomedical Corp.
- 17.13.1 Financial Analysis
- 17.13.2 Product Portfolio
- 17.13.3 Demographic Reach and Achievements
- 17.13.4 Mergers and Acquisition
- 17.13.5 Certifications
- 17.14 Quidel Corporation
- 17.14.1 Financial Analysis
- 17.14.2 Product Portfolio
- 17.14.3 Demographic Reach and Achievements
- 17.14.4 Mergers and Acquisition
- 17.14.5 Certifications
- 17.15 Koninklijke Philips N.V.
- 17.15.1 Financial Analysis
- 17.15.2 Product Portfolio
- 17.15.3 Demographic Reach and Achievements
- 17.15.4 Mergers and Acquisition
- 17.15.5 Certifications
- 18 Global Sepsis Diagnostics Market - Distribution Model (Additional Insight)
- 18.1 Overview
- 18.2 Potential Distributors
- 18.3 Key Parameters for Distribution Partner Assessment
- 19 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 20 Company Competitiveness Analysis (Additional Insight)
- 20.1 Very Small Companies
- 20.2 Small Companies
- 20.3 Mid-Sized Companies
- 20.4 Large Companies
- 20.5 Very Large Companies
- 21 Payment Methods (Additional Insight)
- 21.1 Government Funded
- 21.2 Private Insurance
- 21.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.